×
About 1,933 results

ALLMedicine™ Factor XIII Center

Research & Reviews  957 results

Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experiment...
https://doi.org/10.1182/blood.2020007415
Blood Poole LG, Kopec AK et. al.

Feb 11th, 2021 - Intravascular fibrin clot formation follows a well-ordered series of reactions catalyzed by thrombin cleavage of fibrinogen leading to fibrin polymerization and cross-linking by factor XIIIa (FXIIIa). Extravascular fibrin(ogen) deposits are observ...

Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by p...
https://doi.org/10.1097/MBC.0000000000001020
Blood Coagulation & Fibrinolysis : an International Journ... Morishima Y, Kamisato C et. al.

Feb 9th, 2021 - Previously, we reported that a direct thrombin inhibitor melagatran paradoxically increased thrombin generation in human plasma in the presence of thrombomodulin. The aim of this study is to test the hypothesis that melagatran may exert a deleteri...

Combinations of fibrinolytic gene polymorphisms (plasminogen activator inhibitor type 1...
https://doi.org/10.1097/MBC.0000000000000995
Blood Coagulation & Fibrinolysis : an International Journ... Velickovic J, Jelicic M et. al.

Feb 8th, 2021 - During normal pregnancy depressed fibrinolytic system is caused by changes in many factors, which could be influenced by different gene polymorphisms. The aim of this study was to investigate the combination of fibrinolysis-related gene polymorphi...

Training Program for Home Therapy of People With Factor XIII Deficiency.
https://doi.org/10.1097/PTS.0000000000000823
Journal of Patient Safety; Drumond A, Camelo RM

Jan 29th, 2021 - Training Program for Home Therapy of People With Factor XIII Deficiency.|2021|Drumond A,Camelo RM,|

Prenatal diagnosis of factor 13 deficiency and its recurrence.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757471
BMJ Case Reports; Dasari P, Mangolngnbi Chanu S et. al.

Dec 29th, 2020 - A young third gravida was referred with prenatal diagnosis of factor XIII deficiency at 20 weeks of pregnancy for Medical Termination of Pregnancy (MTP). Her first baby, who was born by emergency Lower Segment Caesarean Section (LSCS) for fetal di...

see more →

Drugs  4 results see all →

Clinicaltrials.gov  967 results

Factor XIII cross-links fibrin(ogen) independent of fibrin polymerization in experiment...
https://doi.org/10.1182/blood.2020007415
Blood Poole LG, Kopec AK et. al.

Feb 11th, 2021 - Intravascular fibrin clot formation follows a well-ordered series of reactions catalyzed by thrombin cleavage of fibrinogen leading to fibrin polymerization and cross-linking by factor XIIIa (FXIIIa). Extravascular fibrin(ogen) deposits are observ...

Prolongation of clot lysis time by a direct thrombin inhibitor melagatran mediated by p...
https://doi.org/10.1097/MBC.0000000000001020
Blood Coagulation & Fibrinolysis : an International Journ... Morishima Y, Kamisato C et. al.

Feb 9th, 2021 - Previously, we reported that a direct thrombin inhibitor melagatran paradoxically increased thrombin generation in human plasma in the presence of thrombomodulin. The aim of this study is to test the hypothesis that melagatran may exert a deleteri...

Combinations of fibrinolytic gene polymorphisms (plasminogen activator inhibitor type 1...
https://doi.org/10.1097/MBC.0000000000000995
Blood Coagulation & Fibrinolysis : an International Journ... Velickovic J, Jelicic M et. al.

Feb 8th, 2021 - During normal pregnancy depressed fibrinolytic system is caused by changes in many factors, which could be influenced by different gene polymorphisms. The aim of this study was to investigate the combination of fibrinolysis-related gene polymorphi...

Training Program for Home Therapy of People With Factor XIII Deficiency.
https://doi.org/10.1097/PTS.0000000000000823
Journal of Patient Safety; Drumond A, Camelo RM

Jan 29th, 2021 - Training Program for Home Therapy of People With Factor XIII Deficiency.|2021|Drumond A,Camelo RM,|

Prenatal diagnosis of factor 13 deficiency and its recurrence.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757471
BMJ Case Reports; Dasari P, Mangolngnbi Chanu S et. al.

Dec 29th, 2020 - A young third gravida was referred with prenatal diagnosis of factor XIII deficiency at 20 weeks of pregnancy for Medical Termination of Pregnancy (MTP). Her first baby, who was born by emergency Lower Segment Caesarean Section (LSCS) for fetal di...

see more →

News  5 results

FXIII replacement may improve hemostasis in acquired hemophilia A
https://www.mdedge.com/hematology-oncology/article/196298/bleeding-disorders/fxiii-replacement-may-improve-hemostasis?channel=27970
Caleb Rans

Mar 13th, 2019 - Measurement of factor XIII levels, followed by replacing deficiencies if found, may help to achieve sustained hemostasis in the management of bleeding in patients with acquired hemophilia A. Jameel Abdulrehman, MD, of the University of Toronto in.

Children under 6 with factor XIII deficiency had no major bleeds with recombinant product
https://www.mdedge.com/familymedicine/article/110923/bleeding-disorders/children-under-6-factor-xiii-deficiency-had-no
Hematology News; Neil Osterweil

Jul 28th, 2016 - ORLANDO –A recombinant form of factor XIII was effective at preventing serious bleeding episodes in young children with factor XIII-A subunit deficiency, a rare and serious bleeding disorder. In a small international phase III trial, there were no.

Use of topical hemostatic agents in gynecologic surgery
https://www.mdedge.com/hematology-oncology/article/89443/gynecologic-cancer/use-topical-hemostatic-agents-gynecologic/page/0/1

Dec 16th, 2014 - Topical thrombins Thrombin (Thrombin-JMI, Evithrom, Recothrom) is derived from bovine, human, or recombinant sources. It converts fibrinogen to fibrin and activates factor XIII, platelets, and smooth muscle constriction (Biologics 2008;2:593-9).

Factor affects thrombus size and content
https://www.mdedge.com/hematology-oncology/article/186765/thrombosis/factor-affects-thrombus-size-and-content
HT Staff

Jul 8th, 2014 - Thrombus Credit: Kevin MacKenzie The activity of transglutaminase factor XIII is critical for retaining red blood cells in a thrombus and therefore affects the clot’s size, investigators have reported in the Journal of Clinical Investigation. The.

FDA Approves First Treatment for Congenital Factor XIII Deficiency
https://www.medscape.com/viewarticle/737875

Feb 22nd, 2011 - February 23, 2011 — The first product intended to prevent bleeding in people with congenital factor XIII deficiency has been approved by the US Food and Drug Administration (FDA). Corifact, manufactured by CSL Behring, received orphan drug designa...

see more →